Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
GS$867.10-61.18(-6.59%)UPDATE 1-Goldman Sachs lowers gold price forecasts on hawkish Fed outlook5:22:31 PM ETMRNA$234.93-23.41(-9.06%)Health Canada Authorizes Moderna's mRNA Influenza and Combination Influenza and COVID-19 Vaccines5:20:44 PM ETAMPH$29.45+1.43(+5.10%)Amphastar Q3 revenue rises, beats expectations5:16:44 PM ETTMO$676.940.00(0.00%)Thermo Fisher Scientific Authorizes $5 Billion of Share Repurchases5:15:01 PM ETPNC$226.750.00(0.00%)PNC names Alexander Overstrom as CFO, succeeding Robert Reilly5:14:20 PM ETDOCU$78.69-1.81(-2.25%)Docusign vs. Monday.com: Which Technology Stock Is a Better Buy for 2027?5:13:02 PM ETRKLB$45.52-6.71(-12.85%)Why Rocket Lab Stock Dropped Today5:11:01 PM ETCOST$1,065.590.00(0.00%)Jim Cramer Says Costco Is Still a Great Value. Charlie Munger's Rule Explains Why5:07:28 PM ETSVM$8.18-0.16(-1.92%)SILVERCORP REPORTS ADJUSTED NET INCOME OF $18.4 MILLION, $0.08 PER SHARE, AND CASH FLOW FROM OPERATING ACTIVITIES OF $62.7 MILLION FOR Q2 FISCAL 20275:06:04 PM ETNET$281.00+36.49(+14.92%)Cloudflare Q3 revenue beats estimates on AI platform demand5:05:25 PM ETINTC$51.70-6.58(-11.29%)Stock Market Today, Nov. 5: Intel Falls on Weak Fourth-Quarter Sales Outlook Amid Chip Selloff5:02:16 PM ETTMO$676.940.00(0.00%)Thermo Fisher Scientific Announces Quarterly Dividend5:00:04 PM ETWPM$129.11-3.35(-2.53%)Wheaton Precious Metals Announces Third Quarter 2026 Results and Record Year-to-Date Production, Sales Volume, Revenue, Earnings and Cash Flow5:00:00 PM ETTSX:SAP$41.620.00(0.00%)Saputo Reports Financial Results for the Second Quarter of Fiscal 2027 Ended September 30, 20265:00:00 PM ETNET$281.00+36.49(+14.92%)Cloudflare Stock Surges on Lifted Full-Year Outlook, Third-Quarter Revenue Growth5:00:00 PM ETMNST$47.830.00(0.00%)Monster Beverage Q3 sales beat estimates as marketing investments boost results4:56:44 PM ETEOG$144.890.00(0.00%)UPDATE 2-US shale producer EOG Resources beats profit estimates on higher crude prices4:55:18 PM ETCVX$213.50+0.57(+0.27%)Chevron (CVX) Price Forecast: Critical Support Faces First Major Test4:54:45 PM ETAAPL$342.79-6.77(-1.94%)Market Close: Stocks Tumble, Apple To Sell $7B In Debt, Wendy's Rejects Buyout Bid 11-5-20264:52:29 PM ETANTUPDATE 1-A&O Shearman's $1.1 billion AI plan builds on law firms' tech investments4:51:58 PM ETDNA$9.50-0.46(-4.62%)Ginkgo Bioworks Q3 revenue falls compared to last year4:51:51 PM ETABX$8.83-0.22(-2.43%)Abacus Global Management Q3 revenue, adjusted EBITDA beat estimates4:51:39 PM ETPRTA$7.89-0.50(-5.96%)Prothena Q3 net loss narrows on lower costs4:51:15 PM ETLRCX$193.16+7.96(+4.30%)BUZZ-Chip firm Lam Research rises after announcing $25 bln stock buyback4:50:28 PM ET

ELVN · NASDAQ

Enliven Therapeutics, Inc.

$44.79 -2.47 (-5.23%)

Company overview

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors includes ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia, and ELVN-002, a Phase 1 clinical trial that has been activated to evaluate patients with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$3.3B
Employees
62
Headquarters
Boulder, CO
Website
enliventherapeutics.com
CEO
Richard A. Fair
Listed
March 12, 2020
P/E
-27.31
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$60,000
Operating income
-$116M
EBITDA
-$111M
Net income
-$98.8M
EPS
-$1.64
Total assets
$465M
Total debt
$302,000
Earnings yield
-3.66%

Price chart

32.3040.0947.8955.6863.47
ELVN 1D NASDAQ O45.74H47.31L44.21C47.25+2.42 (+5.40%)Vol2.71M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
ELVNEnliven Therapeutics, Inc. Stock news Enliven Therapeutics Q3 net loss widens on higher R&D spend Reuters
ELVNEnliven Therapeutics, Inc. Press release Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update PR Newswire
ELVNEnliven Therapeutics, Inc. Press release Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year Enliven Therapeutics, Inc. PR Newswire
ELVNEnliven Therapeutics, Inc. Press release Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia PRNewsWire
ELVNEnliven Therapeutics, Inc. Stock news Enliven Therapeutics (NASDAQ:ELVN) Stock Falls 4.5% Following Insider Selling Defense World
ELVNEnliven Therapeutics, Inc. Stock news This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Benzinga
ELVNEnliven Therapeutics, Inc. Stock news Enliven Therapeutics, Inc. (ELVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Seeking Alpha
ELVNEnliven Therapeutics, Inc. Press release Enliven Therapeutics to Present at Upcoming Investor Conferences PR Newswire
ELVNEnliven Therapeutics, Inc. Stock news Enliven Therapeutics: A Clean Active-Site TKI Could Redefine CML Sequencing Seeking Alpha
ELVNEnliven Therapeutics, Inc. Press release Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting PRNewsWire
ELVNEnliven Therapeutics, Inc. Stock news BlackRock Inc. Invests $221.25 Million in Enliven Therapeutics, Inc. $ELVN Defense World
ELVNEnliven Therapeutics, Inc. Stock news Enliven's Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says Benzinga
ELVNEnliven Therapeutics, Inc. Press release Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update PRNewsWire
ELVNEnliven Therapeutics, Inc. Press release Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress PRNewsWire
ELVNEnliven Therapeutics, Inc. Stock news Enliven Therapeutics' Chief Medical Officer Sold 5,000 Company Shares. Here's What That Means for Investors. Fool - Investing News
ELVNEnliven Therapeutics, Inc. Press release Enliven Therapeutics to Present at Upcoming Investor Conferences PRNewsWire
ELVNEnliven Therapeutics, Inc. Stock news Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120% Fool - Investing News
ELVNEnliven Therapeutics, Inc. Stock news Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company Fool - Investing News
ELVNEnliven Therapeutics, Inc. Stock news Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally Fool - Investing News
ELVNEnliven Therapeutics, Inc. Stock news Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML GuruFocus
See more
FAQ

Questions about Enliven Therapeutics, Inc.

What does Enliven Therapeutics, Inc. do?
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors includes ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia, and ELVN-002, a Phase 1 clinical trial that has been activated to evaluate patients with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
What is ELVN's market cap?
Enliven Therapeutics, Inc. (ELVN) is a listed stock with a live quote. The latest market cap on this page is $3.3B.
Where is Enliven Therapeutics, Inc. headquartered?
Enliven Therapeutics, Inc. is headquartered in Boulder, CO.
How do I get ELVN news from the API?
Call GET /v1/news?tickers=ELVN. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does ELVN news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for ELVN, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the ELVN price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs